<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376063</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-037</org_study_id>
    <nct_id>NCT01376063</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Single-Center, One-Sequence, Open-Label Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the effect of multiple doses of FG-4592 on the
      plasma pharmacokinetic of rosiglitazone in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma concentration of Rosiglitazone</measure>
    <time_frame>Day 1- Day 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma concentration of Rosiglitazone metabolites</measure>
    <time_frame>Day 3 - Day 11</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>FG-4592</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>FG-4592 on days 3,5,7,9
Rosiglitazone maleate on days 1 and 9</description>
    <arm_group_label>FG-4592</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males, 18 to 45 years

          -  Body weight â‰¥ 75 kg

          -  Good health

          -  Non-smoker

          -  Blood pressure not greater than 140/90 mm Hg

        Exclusion Criteria:

          -  Positive for any of the following: Human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg) or anti-hepatitis C virus antibody (anti-HCV Ab)

          -  Blood donation or significant blood loss within 60 days prior to Day 1

          -  Use of prescription and over the counter medications/herbal preparations is not
             allowed within 14 days prior to Day 1 and through treatment phase

          -  History or presence of alcoholism or drug abuse within 2 years prior to Day 1

          -  Consumption of alcohol within 7 days prior to Day 1 or during treatment phase

          -  Positive urine drug/alcohol testing at screening or check-in visit
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>June 17, 2011</last_update_submitted>
  <last_update_submitted_qc>June 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Robert Leong, MD., Medical Monitor</name_title>
    <organization>FibroGen, Inc</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

